New oral anticoagulants for patients with nonvalvular atrial fibrillation

ABSTRACTFour new oral anticoagulants have been approved for reducing stroke risk in patients with nonvalvular atrial fibrillation. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interactions and no regular blood monitoring, although some of the d...

Full description

Saved in:

Bibliographic Details
Published in:	JAAPA (Montvale, N.J.) Vol. 28; no. 11; pp. 28 - 34
Main Authors:	Holden, Amber, Azimi, Nassir, Forest, Christopher P
Format:	Journal Article
Language:	English
Published:	United States Copyright American Academy of Physician Assistants 01-11-2015
Subjects:	Anticoagulants Anticoagulants - therapeutic use Antithrombins - therapeutic use Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Cardiac arrhythmia Dabigatran - therapeutic use Drug dosages Factor Xa Inhibitors - therapeutic use Gastrointestinal diseases Gastrointestinal Hemorrhage - chemically induced Health technology assessment Humans Pharmacology Pyrazoles - therapeutic use Pyridines - therapeutic use Pyridones - therapeutic use Rivaroxaban - therapeutic use Side effects Stroke Stroke - etiology Stroke - prevention & control Thiazoles - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACTFour new oral anticoagulants have been approved for reducing stroke risk in patients with nonvalvular atrial fibrillation. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interactions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1547-1896 0893-7400
DOI:	10.1097/01.JAA.0000471615.92278.1c